Table 3.
Univariate and Multivariate Analyses of Factors Associated With OAC Use vs. No OAC Use and Warfarin Use vs. DOAC Use
| OAC vs. no OAC | Warfarin vs. DOAC | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysisA | Univariate analysis | Multivariate analysisA | |||||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Female sex | 0.80 (0.73–0.86) |
<0.0001 | 0.82 (0.75–0.89) |
<0.0001 | 0.78 (0.74–0.82) |
<0.0001 | 0.75 (0.70–0.79) |
<0.0001 |
| Age ≥85 years | 0.68 (0.63–0.74) |
<0.0001 | 0.63 (0.57–0.68) |
<0.0001 | 1.30 (1.22–1.37) |
<0.0001 | 1.24 (1.17–1.31) |
<0.0001 |
| History of major hemorrhage | 0.60 (0.51–0.71) |
<0.0001 | 0.48 (0.40–0.58) |
<0.0001 | 1.17 (1.03–1.33) |
0.0177 | 1.07 (0.94–1.23) |
0.3103 |
| Persistent or permanent AF | 3.32 (3.05–3.61) |
<0.0001 | 3.21 (2.94–3.50) |
<0.0001 | 1.85 (1.75–1.96) |
<0.0001 | 1.74 (1.65–1.84) |
<0.0001 |
| Hypertension | 1.16 (1.06–1.26) |
0.0015 | 1.27 (1.16–1.39) |
<0.0001 | 0.95 (0.90–1.01) |
0.1099 | 0.92 (0.87–0.98) |
0.0097 |
| Diabetes | 1.19 (1.09–1.31) |
0.0002 | 1.18 (1.07–1.30) |
<0.0001 | 1.15 (1.09–1.22) |
<0.0001 | 1.06 (1.00–1.12) |
0.0664 |
| CKD | 1.11 (1.00–1.22) |
0.0421 | 1.09 (0.98–1.20) |
0.1144 | 1.67 (1.58–1.77) |
<0.0001 | 1.52 (1.43–1.61) |
<0.0001 |
| Heart failure | 1.45 (1.33–1.59) |
<0.0001 | 1.26 (1.15–1.38) |
<0.0001 | 1.38 (1.32–1.46) |
<0.0001 | 1.17 (1.11–1.24) |
<0.0001 |
| Cerebrovascular disease | 1.24 (1.12–1.37) |
<0.0001 | 1.37 (1.23–1.52) |
<0.0001 | 0.99 (0.93–1.05) |
0.6413 | 0.89 (0.84–0.95) |
0.0002 |
| Antiplatelet use | 0.38 (0.35–0.42) |
<0.0001 | 0.34 (0.31–0.38) |
<0.0001 | 1.52 (1.43–1.63) |
<0.0001 | 1.48 (1.39–1.59) |
<0.0001 |
AFactors included in the analysis were sex, age, body mass index, smoking, alcohol consumption, major surgery, history of major bleeding, drug allergy, AF type, non-pharmacotherapy for AF, hypertension, diabetes, dyslipidemia, hyperuricemia, kidney disease, severe liver disorder, respiratory disorder, cardiac disease, cerebral disease, other vascular disease, thyroid disease, digestive disease, active cancer, dementia, other disease, fall within past year, antiarrhythmic agent, antiplatelet agent, anticancer agent, P-glycoprotein inhibitor, polypharmacy, and creatinine clearance. CI, confidence interval; OR, odds ratio. Other abbreviations as in Table 1.